Ionis Reports Strong Q2 2026 Growth on TRYNGOLZA Launch and Pipeline Progress — Ionis Pharmaceuticals, Inc.

Event summary

Ionis reported Q2 2026 revenue of $268M, up 56% YoY excluding a one-time payment from 2025.
TRYNGOLZA generated $32M in net product sales in the first half of 2026, with full-year guidance of $100-110M.
DAWNZERA sales increased 63% QoQ to $26M, on track for $110-120M in full-year 2026 sales.
Zilganersen NDA under FDA Priority Review with PDUFA target action date of September 22, 2026.
Bepirovirsen on track for global launch this year with U.S. PDUFA target action date of October 26, 2026.

The big picture

Ionis is leveraging its RNA-targeted medicine expertise to drive commercial growth through independent launches like TRYNGOLZA and DAWNZERA, while positioning itself for additional regulatory milestones with zilganersen and bepirovirsen. The company's strategic focus on neurology and cardiometabolic diseases aligns with high-unmet medical needs, potentially offering long-term value creation. With a strong cash position of $2.1B and a goal of cashflow breakeven in 2028, Ionis is balancing aggressive commercialization efforts with disciplined financial management.

What we're watching

Commercial Momentum: Whether Ionis can sustain the early launch momentum of TRYNGOLZA and DAWNZERA through the second half of 2026.
Regulatory Milestones: The pace at which zilganersen and bepirovirsen secure regulatory approvals, which could drive significant revenue growth.
Pipeline Execution: How Ionis advances its other pipeline programs, particularly obudanersen for Angelman syndrome and ION775 for sHTG.